EirGenix Inc. (6589) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of EirGenix Inc. stock TWD 40.83, price TWD 53.20, that is 23.3% below the price, quality 50 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
EirGenix Inc.
6589 · TWExpensive (fair value 23% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range 40.55 TWD – 178.00 TWD · fair‑value band 30.62 TWD – 51.03 TWD · the 53.20 TWD price screens above the 40.83 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether EirGenix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.
Show moreShow less
It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.
In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Stock analysis
EirGenix Inc. (6589) currently trades at 53.20 TWD, while our estimate is 40.83 TWD, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 30.62 TWD (bear) to 51.03 TWD (bull), the price of 53.20 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
EirGenix Inc. reported revenue of 1.0B TWD in FY2025 versus 1.7B TWD in FY2021, a compound −12.3%/yr. Reported net income was −761M TWD in FY2025.
Key figures
Market cap 16.1B TWD (≈ $488M) Small · P/S ratio 13.7 · EPS (TTM) −1.89 TWD · Net margin −46.9% · Return on equity −7.0% · Return on assets (EBIT) −5.6% (5-year average) · Operating margin −70.7% · Revenue (TTM) 1.2B TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −23%, 6589 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare EirGenix Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 6589 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 6589 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 6589 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 6589 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 6589 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 6589 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 6589 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 6589 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 6589 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 6589 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is EirGenix Inc. (6589) overvalued or undervalued?
What is the fair value of 6589?
What is the quality score of 6589?
What is the price target for EirGenix Inc. (6589)?
What is the EirGenix Inc. stock forecast for 2026?
What is the revenue of EirGenix Inc. (6589)?
What is the intrinsic value of EirGenix Inc. (6589)?
Is EirGenix Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 6589?
How much is EirGenix Inc. worth?
What do the bullish and bearish scenarios say about 6589?
How solid is the balance sheet of EirGenix Inc. (6589)?
How far is 6589 from its 52-week high?
Which stocks are comparable to EirGenix Inc.?
Is EirGenix Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of EirGenix Inc. (6589)?
What should I pay attention to with EirGenix Inc. right now?
Key figures of EirGenix Inc.
How large is the market capitalisation of EirGenix Inc. (6589)?
What is the P/S ratio of EirGenix Inc. (6589)?
What are the earnings per share of EirGenix Inc. (6589)?
What is the net margin of EirGenix Inc. (6589)?
What is the return on equity of EirGenix Inc. (6589)?
What is the EBIT return on assets of EirGenix Inc. (6589)?
What is the operating margin of EirGenix Inc. (6589)?
How fast is revenue growing at EirGenix Inc. (6589)?
How much free cash flow does EirGenix Inc. (6589) generate?
Watch EirGenix Inc. in the live analysis
One click puts EirGenix Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.